Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Objective: Understanding how different parts of the immune system contribute to pathogenesis in Parkinson's disease is a burning challenge with important therapeutic implications. We studied enrichment of common variant heritability for Parkinson's disease stratified by immune and brain cell types. Methods: We used summary statistics from the most recent meta‐analysis of genomewide association studies in Parkinson's disease and partitioned heritability using linkage disequilibrium score regression, stratified for specific cell types, as defined by open chromatin regions. We also validated enrichment results using a polygenic risk score approach and intersected disease‐associated variants with epigenetic data and expression quantitative loci to nominate and explore a putative microglial locus. Results: We found significant enrichment of Parkinson's disease risk heritability in open chromatin regions of microglia and monocytes. Genomic annotations overlapped substantially between these 2 cell types, and only the enrichment signal for microglia remained significant in a joint model. We present evidence suggesting P2RY12 , a key microglial gene and target for the antithrombotic agent clopidogrel, as the likely driver of a significant Parkinson's disease association signal on chromosome 3. Interpretation: Our results provide further support for the importance of immune mechanisms in Parkinson's disease pathogenesis, highlight microglial dysregulation as a contributing etiological factor, and nominate a targetable microglial gene candidate as a pathogenic player. Immune processes can be modulated by therapy, with potentially important clinical implications for future treatment in Parkinson's disease. ANN NEUROL 2021;89:942–951
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationUnraveling the polygenic architecture of complex traits using blood eQTL metaanalysis
Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Kasela, S., et al. (2018) · doi:10.1101/447367 · Cited by 2,607
Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M. J., Deelen, P., Zeng, B., Kirsten, H., Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00913-z · Cited by 2,607
Partitioning heritability by functional annotation using genome-wide association summary statistics
ReproGen Consortium, Finucane, H. K., Schizophrenia Working Group of the Psychiatric Genomics Consortium, The RACI Consortium, Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila, V., et al. (2015) · Nature Genetics · doi:10.1038/ng.3404 · Cited by 2,604 · cited 3×
“We applied s-LDSC to partition heritability for PD across tissue and cell-type annotations and assessed enrichment, following the method as described by Finucane et al. 23 We used downloadable LD scores estimated from 1000 Genomes data and included single-nucleotide polymorphisms (SNPs) present in HapMap 3 with an all…”
MethodInfluentialVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967
Analysis of shared heritability in common disorders of the brain
The Brainstorm Consortium, Anttila, V., Bulik-Sullivan, B., Finucane, H. K., Walters, R. K., Bras, J., Duncan, L., Escott-Price, V., Falcone, G. J., Gormley, P., et al. (2018) · Science · doi:10.1126/science.aap8757 · Cited by 1,924
Self-citationThe Encyclopedia of DNA elements (ENCODE): data portal update
Davis, C. A., Hitz, B. C., Sloan, C. A., Chan, E. T., Davidson, J. M., Gabdank, I., Hilton, J. A., Jain, K., Baymuradov, U. K., Narayanan, A. K., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1081 · Cited by 1,717
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474
An environment-dependent transcriptional network specifies human microglia identity
Gosselin, D., Skola, D., Coufal, N. G., Holtman, I. R., Schlachetzki, J. C. M., Sajti, E., Jaeger, B. N., O’Connor, C., Fitzpatrick, C., Pasillas, M. P., et al. (2017) · Science · doi:10.1126/science.aal3222 · Cited by 1,220
Self-citationCorces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., Snyder, M. P., Pritchard, J. K., Kundaje, A., Greenleaf, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3646 · Cited by 1,151
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112
Finucane, H. K., Reshef, Y. A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., Loh, P.-R., Lareau, C., Shoresh, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0081-4 · Cited by 1,097
The myeloid cells of the central nervous system parenchyma
Ransohoff, R. M., & Cardona, A. E. (2010) · Nature · doi:10.1038/nature09615 · Cited by 804
Transcriptomic analysis of purified human cortical microglia reveals age-associated changes
Galatro, T. F., Holtman, I. R., Lerario, A. M., Vainchtein, I. D., Brouwer, N., Sola, P. R., Veras, M. M., Pereira, T. F., Leite, R. E. P., Möller, T., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4597 · Cited by 741 · cited 1×
“P2RY12 encodes the ADP receptor purinergic receptor P2Y, G protein-coupled 12, whose expression is often reported in the neuroscience literature as a marker of homeostatic, nonactivated microglia.(38) Disease-associated activation of microglia is associated with downregulation of P2RY12, coupled with upregulation of o…”
BackgroundSelf-citationBrain cell type–specific enhancer–promoter interactome maps and disease - risk association
Nott, A., Holtman, I. R., Coufal, N. G., Schlachetzki, J. C. M., Yu, M., Hu, R., Han, C. Z., Pena, M., Xiao, J., Wu, Y., et al. (2019) · Science · doi:10.1126/science.aay0793 · Cited by 699 · cited 16×
“35 Very shortly before submission of our article, a preprint (not yet peer reviewed) was published mapping microglia-speci fi c eQTLs to brain disorders, also nominating P2RY12 in PD. 37 It should be emphasized, however, that current evidence is all based on associations, and that functional studies in relevant experim…”
BackgroundMethodInfluentialSelf-citationThe role of peripheral immune cells in the CNS in steady state and disease
Prinz, M., & Priller, J. (2017) · Nature Neuroscience · doi:10.1038/nn.4475 · Cited by 657
Genetic variability in the regulation of gene expression in ten regions of the human brain
UK Brain Expression Consortium, Ramasamy, A., North American Brain Expression Consortium, Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De, T., Coin, L., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3801 · Cited by 644
Self-citationPolarization of the Effects of Autoimmune and Neurodegenerative Risk Alleles in Leukocytes
Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M. N., Replogle, J. M., Feng, T., Lee, M., Asinovski, N., Frohlich, I., et al. (2014) · Science · doi:10.1126/science.1249547 · Cited by 506 · cited 11×
“35 Very shortly before submission of our article, a preprint (not yet peer reviewed) was published mapping microglia-speci fi c eQTLs to brain disorders, also nominating P2RY12 in PD. 37 It should be emphasized, however, that current evidence is all based on associations, and that functional studies in relevant experim…”
BackgroundInfluentialAn xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome
Ng, B., White, C. C., Klein, H.-U., Sieberts, S. K., McCabe, C., Patrick, E., Xu, J., Yu, L., Gaiteri, C., Bennett, D. A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4632 · Cited by 452
Purinergic receptor P2RY12-dependent microglial closure of the injured blood–brain barrier
Lou, N., Takano, T., Pei, Y., Xavier, A. L., Goldman, S. A., & Nedergaard, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520398113 · Cited by 364 · cited 1×
“thrombotic compound clopidogrel, which has been shown experimentally to inhibit microglial P2RY12 in the context of blood-brain barrier breakdown.(43) Further studies are clearly needed, but given that fact that this molecule is an established drug-target, we anticipate potentially important clinical implications if m…”
BackgroundLopes, K. D. P., Snijders, G. J. L., Humphrey, J., Allan, A., Sneeboer, M. A. M., Navarro, E., Schilder, B. M., Vialle, R. A., Parks, M., Missall, R., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-00976-y · Cited by 273
Tansey, K. E., Cameron, D., & Hill, M. J. (2018) · Genome Medicine · doi:10.1186/s13073-018-0523-8 · Cited by 115
Lu, Q., Powles, R. L., Abdallah, S., Ou, D., Wang, Q., Hu, Y., Lu, Y., Liu, W., Li, B., Mukherjee, S., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006933 · Cited by 97
The Parkinson's Disease Genome‐Wide Association Study Locus Browser
Grenn, F. P., Kim, J. J., Makarious, M. B., Iwaki, H., Illarionova, A., Brolin, K., Kluss, J. H., Schumacher‐Schuh, A. F., Leonard, H., Faghri, F., et al. (2020) · Movement Disorders · doi:10.1002/mds.28197 · Cited by 92 · cited 2×
“A PD GWAS locus browser was launched in 2020, summarizing the evidence supporting causality for specific genes at significant GWAS loci.(35) The article presenting the browser also highlighted P2RY12 as an example of a strong functional candidate, top ranked in the locus based on brain(29,31) and blood(36) eQTL data,…”
ResultSelf-citationGenomics implicates adaptive and innate immunity in Alzheimer’s and Parkinson’s diseases
Gagliano, S. A., Pouget, J. G., Hardy, J., Knight, J., Barnes, M. R., Ryten, M., & Weale, M. E. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.369 · Cited by 85
Self-citation
Cited by
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
Kou, L., Chi, X., Sun, Y., Han, C., Wan, F., Hu, J., Yin, S., Wu, J., Li, Y., Zhou, Q., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02494-y · Cited by 109
“of MPTP‐induced mice Glial activation is an important pathological marker of PD neuroinflammation [28, 29].”
BackgroundAssociation of a common genetic variant with Parkinson’s disease is mediated by microglia
Langston, R. G., Beilina, A., Reed, X., Kaganovich, A., Singleton, A. B., Blauwendraat, C., Gibbs, J. R., & Cookson, M. R. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8869 · Cited by 93
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Metadata
- Authors
- Andersen, M. S., Bandres‐Ciga, S., Reynolds, R. H., Hardy, J., Ryten, M., Krohn, L., Gan‐Or, Z., Holtman, I. R., Pihlstrøm, L., & the International Parkinson's Disease Genomics Consortium
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2021-03-04
- Volume
- 89
- Issue
- 5
- Pages
- 942-951
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3109706750
- Cited by
- 60
- References
- 26
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.